increase font size
Head OfficeClinuvel Pharmaceuticals Limited, Tel: +61 3 9660 4900 |
Swiss OfficeNeuhofstrasse 3D Tel: +41 41 767 4545 |
US Office40 Worth Street, Fax: +1 646 527 7309 |
Clinuvel receives a large number of inquiries every day. For a list of frequently asked questions, including information on projected release dates and trial participation please click here.
For more information on Clinuvel’s program for SCENESSE® in vitiligo, please go to http://www.clinuvel.com/vitiligo.
Today, February 28, marks Rare Disease Day: an annual event to help highlight the effects of rare diseases on individuals, families and the...
Read MoreWe've just released the first results from our vitiligo program which you can view online here. Following their release, we expect a number...
Read More
I find vitiligo to be a fascinating, yet devastating disorder: almost overnight, patients see their skin colour erode and their identity...
Read More
Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut... Watch now |
Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut... Watch now |
Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut... Watch now |
The technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology and has spent over A$20million optimising the chemistry of afamelanotide (the active ingredient in SCENESSE®) an... Read more |
